Outcomes with KTE-X19 in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) in ZUMA-2 who had progression of disease within 24 months of diagnosis (POD24).
Year: 2021
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Michael Wang, Javier Munoz, Andre Goy, Frederick Lundry Locke, Caron A. Jacobson, Brian T. Hill, John Timmerman, Houston Holmes, Samantha Jaglowski, Ian Flinn, Peter A. McSweeney, David Bernard Miklos, Marie José Kersten, Krimo Bouabdallah, Max S. Topp, Rhine Shen, Ioana Kloos, Weimin Peng, Xiang Fang, Patrick M. Reagan
Institutions: The University of Texas MD Anderson Cancer Center, Banner MD Anderson Cancer Center, Hackensack University Medical Center, Moffitt Cancer Center, Dana-Farber Cancer Institute, Cleveland Clinic, University of California, Los Angeles, Texas Oncology, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Sarah Cannon, Tennessee Oncology, Colorado Blood Cancer Institute, Stanford Medicine, Stanford University, Amsterdam University Medical Centers, University of Amsterdam, Centre Hospitalier Universitaire de Bordeaux, University of Würzburg, Universitätsklinikum Würzburg, University of Rochester Medicine
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3172497218